Neurology® Podcast

The first interview is with Dr. Michelle Fullard and Dr. John Winkleman on the topic of RLS and RLS treatment. The second is with Dr. Jeff Ratliff and Dr. Anhar Hassan on orthostatic tremor. These interviews originally appeared on December 13, 2016 and February 2, 2016, respectively. In the third week's interview, originally released on June 7, 2016, Dr. Fullard talks with Dr. Mark LeDoux on the topic of cervical dystonia. In the fourth and final interview, from September 27, 2016, Dr. Ted Burns speaks with Mrs. Susan Schneider Williams about her late husband Robin Williams's Lewy Body Disease.

1) Symptoms from Repeated Intentional and Unintentional Head Impact in Soccer Players2) What's Trending: Nusinersen for treatment of spinal muscular atrophy3) Topic of the Month: Neurology Today® paper on pulmonary embolismThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 28, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Michael Lipton about his paper on repeated head impact in soccer players. Dr. Ted Burns talks with Dr. Richard Finkel about his recent study on nusinersen as a promising treatment for spinal muscular atrophy for our "What's Trending" feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Sofia Barbar on a Neurology Today story about her article on pulmonary embolism. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Lipton has served on the scientific advisory boards of Guerbet and Bracco; has served on the editorial boards of the American Journal of Neuroimaging and Brain Imaging and Behavior; holds a patent on EZ-MAP image processing software; receives publishing royalties from Springer; has been a consultant for Bracco; and has received research support from Philips Medical Systems, NIH/NINDS, NIH/NIA, NIH/NICHD, the Dana Foundation, and the Resurrecting Lives Foundation.Dr. Finkel has served on the scientific advisory boards of Families of SMA, Nationwide Children's Hospital, SMA Europe, Pediatric Neuromuscular Clinical Research Network, and SMA REACH (UK); has received travel funding from Families of SMA, SMA Foundation, and the Muscular Dystrophy Association; has received travel funding and speaker honoraria from Ionis Pharmaceuticals; serves on the editorial boards of Neuromuscular Disorders and the Journal of Neuromuscular Diseases (additionally, spouse serves on editorial board of Arthritis Research and Therapy); his spouse holds patents for Mouse Anti-TCR Zeta Antibody to Southern Biotechnology Associate, Anti-Human TCR Zeta mAb to Upstate Pharmaceuticals, and Anti-Human TCR Zeta mAb to Santa Cruz Biotechnology; he receives publishing royalties from Elsevier; has been a consultant for Ionis Pharmaceuticals, Biogen, Roche, Novartis, Motobridge, Capricor, Lilly, and Summit; spends approximately 30% of his time working with spinal muscular atrophy patients; has received research support from Isis Pharmaceuticals, Biogen, Eli Lilly Pharmaceuticals, Cytokinetics, RevereGen, BMS, Summit, Sarepta, NIH, the Spinal Muscular Atrophy Foundation, Families of Spinal Muscular Atrophy, the Muscular Dystrophy Association, and the Charcot-Marie-Tooth Association; and his spouse receives licensing fee payments for aforementioned patents.All other participants have no disclosures.

1) Microarray screening of Guillain-Barré syndrome sera for antibodies to glycolipid complexes2) What's Trending: video gaming in children 3) Topic of the Month: Neurology Today® paper on mitochondrial replacementThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Hugh Willison about his Neurology® Neuroimmunology & Neuroinflammation paper on microarray screening of autoantibodies to glycolipid complexes in Guillain-Barre syndrome. Dr. Ted Burns talks with Dr. Gerard Martínez Vilavella about video gaming in children for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Shoukhrat Mitalipov on mitochondrial replacement for genetic diseases. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Willison serves on the scientific advisory board for Wellcome Trust; serves on editorial boards for Nature Clinical Practice Neurology; Journal of Neuroimmunology, Muscle and Nerve, J Peripheral Nervous System, BMC Neurology (Associate Editor), Clinical and Experimental Neuroimmunology, and Experimental Neurology; holds a patent for combinatorial glycoarray technology; and receives research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., Medical Research Council, and Wellcome Trust. Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer" (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.All other participants report no disclosures.

1) Prognosis of carotid dissecting aneurysms: results from CADISS and a systematic review2) What's Trending: CRISPR gene editing in neuromuscular diseases3) Neurology Today® paper – spotlight on Dr. John NoseworthyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 14, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Hugh Markus about his paper on the prognosis of carotid dissecting aneurysms. For our "What's Trending" feature of the week, Dr. Ted Burns interviews Dr. Eric Olson regarding CRISPR at the 2016 AANEM meeting. In the next part of the podcast, Dr. Ted Burns speaks with Mayo Clinic CEO Dr. John Noseworthy about his meeting with President Trump and his experience as Editor-in-Chief of Neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Markus has served on the editorial boards of the International Journal of Stroke, Clinical Neurology and Neurosurgery, BMC Medicine, and Frontiers in Neurology; receives publishing royalties from Oxford University Press; has received reimbursement from Astra Zeneca for teaching a session to employees; and has received research support from NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Noseworthy receives publishing royalties for the following publications: Fifty Neurologic Cases, Oxford, 2004, Multiple Sclerosis 2, Blue Books; Butterworth, 2003, Neurologic Therapeutics, Edition 1, Martin Dunitz, 2003, Neurologic Therapeutices, Edtion 2, Informa, 2006, McAlpine's Multiple Sclerosis, 4th Edition, 2006.All other participants have no disclosures.

1) Dystonia treatment: patterns of medication use in an international cohort2) What's Trending: Without Borders global neurology site 3) Topic of the Month: Neurology Today® paper on the expansion of teleneurologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 7, 2017 issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Sarah Pirio Richardson about her paper on patterns of medication use in dystonia treatment. Dr. Ted Burns talks with Dr. Gretchen Birbeck about the Without Borders global neurology site for our "What's Trending" feature of the week. In the next part of the podcast Dr. Andy Southerland focuses his interview with Dr. Larry Wechsler on a Neurology Today® story about the expansion of teleneurology. Disclosures can be found at Neurology.org. DISCLOSURES:Dr. Willison serves on a scientific advisory board and receives research support from Wellcome Trust; possesses a patent for combinatorial glycoarray technology; and has received research support from Ipsen, Annexon Biosciences, Alexion Pharmaceuticals, Inc., and the Medical Research Council.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Pirio Richardson receives research support from the NIH.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Birbeck serves on scientific advisory board for Lift the Burden Global Campaign against Headache Board; curates the Neurology®: Without Borders site; and receives research support from the NIH.Dr. Wechsler serves on scientific advisory boards for Remedy Pharmaceuticals, Inc., Forest Devices, and Silk Road Medical, Inc.; receives research support from NIH/NINDS and Athersys, Inc., and SanBio Co. Ltd.; provides telestroke services through UPMC Telemedicine network; and holds stock options in Silk Road Medical, Inc. Remedy Pharmaceuticals, Inc., and Forest Devices. Dr. Ratliff reports no disclosures.

Interviews regarding the CDC guidelines on prescribing opioids

Show description/summary:1) Progressive rural-urban disparity in acute stroke care2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 31, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Allison Willis about her paper on disparities in stroke care between rural and urban areas. Dr. Ted Burns talks with Dr. Eric Olsen regarding CRISPR at the 2016 AANEM meeting for our "What's Trending" feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Merit Cudkowicz on amyotrophic lateral sclerosis (ALS). Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Allison Willis has served on the editorial board of Pharmacoepidemiology and Drug Safety; and has received research support from NIH/NINDS.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Merit Cudkowicz has served on the editorial board of DSMB AstraZenica (through Clintrex); has served on the editorial boards of Neurotherapeutics and JAMA Neurology; holds a patent for Metabolomics in ALS; receives publishing royalties from UpToDate; has been a consultant for Cytokinetics, Biogen-Idec, Voyager, Biohaven, Astrazenica, Genentech, Karyopharm, and Neuraltis; has received research support from NINDS, the Muscular Dystrophy Association, the ALS Association, and the ALS Finding a Cure Association; and has provided expert witness for defense (TEVA).All other participants have no disclosures.

1) Relationship between Risk Factor Control and Vascular Events in the SAMMPRIS Trial 2) What's Trending: 2017 AAN Annual Meeting3) Topic of the Month: neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 24, 2017 issue of Neurology. In the first segment, Dr. Joseph Carrera talks with Dr. Tanya Turan about her paper on risk factor control and vascular events in the SAMMPRIS trial. Dr. Ted Burns talks with Christy Phelps about the 2017 AAN Annual Meeting for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Anthony Amato on myositis. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Turan serves on a scientific advisory board for Boehringer Ingelheim; serves on blinded Neurological Events Adjudication Committees for Boehringer Ingelheim and W.L. Gore and Associates; is Review Editor for Frontiers in Endovascular and Interventional Neurology and specialty editor of Frontiers in Neurology; serves on editorial boards for World Journal of Neurology, Brain and Behavior, and Annals of Translational Medicine; and received research support from NIH/NINDS K23 award for activities in the SAMMPRIS trial.Dr. Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Amato serves on medical advisory boards for MedImmune, Amgen, Novartis, DART, Biogen, Acceleron, and DSMB for NIH; is Associate Editor for Neurology and Muscle & Nerve; possesses publishing royalties for Neuromuscular Disease (McGraw-Hill 2016); serves as medical consultant for MedImmune, Amgen, Biogen, Novartis, Acceleron, Analgesic Solutions, Up-to-Date, and Best Doctors; and receives research support from Novartis, Alexion, and Amgen.Christy Phelps serves as Deputy Executive Director for the AAN.Dr. Carrera reports no disclosures.

1) Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 17, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Aneesh Singhal about his paper on glucocorticoid-associated worsening of reversible cerebral vasoconstriction syndrome. Dr. Ted Burns talks with Dr. Roy Strowd about upcoming changes regarding the Neurology Resident & Fellow section for our "What's Trending" feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Volker Straub on limb-girdle dystrophy. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review. Dr. Aneesh Singhal has served on the scientific advisory boards of Biogen and DSMB; has served on the editorial board of Medical Gas Research; has received publishing royalties for the book Reversible Cerebral Vasoconstriction Syndromes; has been a consultant to Biogen; has acted as an event adjudicator for the Thrombolysis in Myocardial Infarction (TIMI) Trial Group; has received research support from Boehringer Ingelheim, NIH-NINDS, the American Academy of Neurology, UpToDate, and Medlink; and has served as a medicolegal expert witness for individual cases concerning stroke. Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Straub has served on the scientific advisory boards for Pfizer, Italfarmaco, Audentes Therapeutics, Bristol-Myer Squibb, Summit Therapeutics, Tivorsan, and the Nationwide Children's Hospital; has received travel funding and speaker honoraria from Sanofi Genzyme; has served on the editorial boards of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and PLoS Currents Muscular Dystrophy; has been a consultant for Sanofi Genzyme; and has received research support from Sanofi Genzyme, BioMarin, Ionis Pharmaceuticals, Sarepta Therapeutics, Ultragenyx, the European Commission, the UK Medical Research Council, Newcastle University, the Parent Project Muscular Dystrophy, the Association Fracaise Contre les Myopathies, the LGMD2I Research Fund, the Wellcome Trust, the Sylvia Aitken Charitable Trust, Muscular Dystrophy UK, and Action Medical Research.All other participants have no disclosures.

1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our "What's Trending" feature of the week. In the next part of the podcast Dr. Ted Burns focuses his interview with Dr. Gil Wolfe on myasthenia gravis. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. McGarry serves on an advisory board for Teva Pharmaceutical Industries, Ltd.; receives speaker honoraria for Teva Pharmaceutical Industries, Ltd. and ACADIA Pharmaceuticals, Inc.; and has received research support from Teva Pharmaceutical Industries, Ltd. and NINDS. Dr. Ramchandren received research support from the NIH.Dr. Wolfe advises for Grifols, Baxalta, Argenx, and UCB; receives speaker honoraria for Grifols and Baxalta; receives research support from CSL Behring; and serves as Associate Editor for Muscle and Nerve. Dr. Fullard reports no disclosures.